A Phase II Trial of Tazemetostat Plus Mosunetuzumab In Untreated Follicular Lymphoma

The purpose of this study is to test the efficacy of the combination of tazemetostat with mosunetuzumab and see what effects it has in your lymphoma. Tazemetostat is a drug that inhibits (reduces the ability of) EZH2, an enzyme known to drive the development of B-cell lymphomas, and inhibiting it appears to have many effects that slow down lymphoma growth and enhance the immune system’s ability to fight it. Tazemetostat is Food and Drug Administration (FDA) approved in previously treated follicular lymphoma and currently undergoing study in other lymphomas. Mosunetuzumab is a bispecific antibody therapy that is a therapeutic strategy that uses the immune system to fight lymphoma, called immunotherapy. Mosunetuzumab has been studied in follicular lymphoma that has previously been treated, with positive results. Mosunetuzumab is approved by the FDA to be given intravenously (directly into a vein) but is not approved by the FDA as an injection under the skin, which is how it is given in this study. These drugs have not yet been studied in combination. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

Are you Eligible? (Inclusion Criteria)

• Must be 18 years or older - Have been diagnosed with Follicular Lymphoma - Must be able to take oral medication